Cognition Therapeutics Inc.
CGTX | NASDAQ
$1.01
+$0.01 (+1.00%)
Sep 22, 2026, 11:22 AM ET · Market open
+1.00%
(1D)Rating
Updated: Aug 31, 2026Key Statistics
Market Data
Market Cap $90.39M
1D Range
1 1.03
52W Range
0.55 2.05
Valuation (TTM)
PE -5.26
PB 2.71
EV/EBITDA -2.75
Valuation (NTM)
Forward PE N/A
Forward PEG 0.20
Price Target $3
Cash Flow
FCF Yield -19.8%
SBC Adj. FCF Yield -20.9%
SBC Impact -5.7%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 62.0% |
13.6%
FCF 3Y | 5Y 11.1% |
-14.5%
Returns
ROA -43.1%
ROE -50.2%
ROIC -109.1%
Financial Health
Net Cash
$33.5M
Current Ratio 7.03
Interest Coverage -2,815.46
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are prima...
Sector Healthcare
Industry Biotechnology
Employees 14
IPO Date Oct 7, 2021
Website www.cogrx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$3
Upside
+197.03%
Buy (3)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove CGTX